File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses

TitleA recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
Authors
KeywordsInfluenza A virus
H5N1
Hemagglutinin
Recombinant vaccine
Cross-protection
Issue Date2011
PublisherAkademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology
Citation
The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11 How to Cite?
Abstract
Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
DescriptionPoster abstracts - Session D: Viral Infections and Vaccines
Persistent Identifierhttp://hdl.handle.net/10722/135939
ISSN

 

DC FieldValueLanguage
dc.contributor.authorDu, Len_US
dc.contributor.authorLeung, VHCen_US
dc.contributor.authorJiang, Sen_US
dc.contributor.authorZheng, Ben_US
dc.date.accessioned2011-07-27T02:00:10Z-
dc.date.available2011-07-27T02:00:10Z-
dc.date.issued2011en_US
dc.identifier.citationThe 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11en_US
dc.identifier.issn2062-509X-
dc.identifier.urihttp://hdl.handle.net/10722/135939-
dc.descriptionPoster abstracts - Session D: Viral Infections and Vaccines-
dc.description.abstractDevelopment of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.-
dc.languageengen_US
dc.publisherAkademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology-
dc.relation.ispartofEuropean Journal of Microbiology and Immunologyen_US
dc.subjectInfluenza A virus-
dc.subjectH5N1-
dc.subjectHemagglutinin-
dc.subjectRecombinant vaccine-
dc.subjectCross-protection-
dc.titleA recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 virusesen_US
dc.typeConference_Paperen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=2062-509X&volume=1&issue=2&spage=182, abstract no. D11&epage=&date=2011&atitle=A+recombinant+vaccine+of+H5N1+HA1+fused+with+foldon+and+human+IgG+Fc+induced+complete+cross-clade+protection+against+divergent+H5N1+viruses-
dc.identifier.emailLeung, VHC: virtualgraffiti@yahoo.com.hken_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hk-
dc.identifier.authorityZheng, B=rp00353en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1556/EuJMI.1.2011.2.1-
dc.identifier.hkuros188738en_US
dc.identifier.volume1-
dc.identifier.issue2-
dc.identifier.spage182-
dc.identifier.epage182-
dc.description.otherThe 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats